课题基金 / 基金详情

项目摘要

项目成果

GARTH POWIS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT Thioredoxin family members involved in cellular protein signaling networks provide an important mechanism regulating many aspects of cell function including proliferation and cell survival. Redox signaling involves a protein post translational modification second in importance only to protein phosphorylation. Unlike protein phosphorylation little is known of redox signaling networks in the cell or how they are altered in cancer. The increased expression of one redox signaling protein in particular thioredoxin-1 (Trx-1) has been associated with aggressive tumor growth, decreased apoptotic cell death and decreased patient survival. The hypothesis upon which our studies are based is that redox signaling through thioredoxin family members is an important signaling mechanism that is deranged in cancer and that understanding redox signaling networks in the cancer cell will allow the identification of novel molecular targets for cancer drug discovery and development, and new strategies to treat cancer. We have used Drosophila genetics together with functional genetic siRNA studies in human cancer cells to identify new redox signaling pathways which we will investigate in human cancer cells. We will also investigate the redox regulation of the unfolded protein response (UPR) which is important for maintaining the synthesis of cell survival proteins during stress, including many angiogenic factors important in cancer. We will conduct in vivo antitumor and mechanistic studies of an inhibitor of Trx-1 in colorectal cancer and of a new antitumor inhibitor of thioredoxin reductase we have developed. The overall objective of our studies is to use redox signaling pathways in cancer to identify new molecular targets for cancer drug discovery and development, and to provide new strategies to treat cancer. The work builds upon our past studies of Trx-1 as a cancer drug target which has led to the development of one cancer drug in clinical trial, and seeks to identify new pathways of redox signaling by thioredoxin family members for the identification of molecular targets for cancer drug discovery.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 2005-01
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者: [B. Jordan;M. Runquist;N. Raghunand;R. Gillies;W. Tate;G. Powis;A. Baker]
通讯作者: B. Jordan;M. Runquist;N. Raghunand;R. Gillies;W. Tate;G. Powis;A. Baker
DOI: 10.1007/s00280-010-1500-0
发表时间: 2011-08
期刊: CANCER CHEMOTHERAPY AND PHARMACOLOGY
影响因子: 3
作者: [Kim, Yon Hui, Coon, Amy, Baker, Amanda F., Powis, Garth]
通讯作者: Powis, Garth
DOI: 10.1007/s12274-009-9026-7
发表时间: 2009-04-17
期刊: NANO RESEARCH
影响因子: 9.9
作者: [Bartholomeusz, Geoffrey, Cherukuri, Paul, Kingston, John, Cognet, Laurent, Lemos, Robert, Jr., Leeuw, Tonya K., Gumbiner-Russo, Laura, Weisman, R. Bruce, Powis, Garth]
通讯作者: Powis, Garth
DOI: 10.1016/j.freeradbiomed.2008.12.012
发表时间: 2009-03-15
期刊: FREE RADICAL BIOLOGY AND MEDICINE
影响因子: 7.4
作者: [James, Brian P., Staatz, William D., Wilkinson, Sarah T., Meuillet, Emmanuelle, Powis, Garth]
通讯作者: Powis, Garth
Targeting ERK5 for Colorectal Cancer Therapy
Targeting ERK5 for Colorectal Cancer Therapy
  • 批准号:
    10357462
  • 项目类别:
  • 资助金额:
    $16.95万
  • 财政年份:
    2020
  • 负责人:
    GARTH POWIS
  • 依托单位:
Inhibiting Multi-Functional ALDOA for Cancer Therapy
  • 批准号:
    10357451
  • 项目类别:
  • 资助金额:
    $50.46万
  • 财政年份:
    2018
  • 负责人:
    GARTH POWIS
  • 依托单位:
Inhibiting Multi-Functional ALDOA for Cancer Therapy
  • 批准号:
    10494262
  • 项目类别:
  • 资助金额:
    $49.81万
  • 财政年份:
    2018
  • 负责人:
    GARTH POWIS
  • 依托单位:
海外基金